Operator
Wonderful. Maybe, for those who might be newer to the story, can you give us a brief overview of the company? And again, you’ve evolved from a successful discovery partner into a company now focused on advancing its own clinical assets. How did that evolution happen?
Carl L. Hansen
CEO, President & Chairperson
Sure. So the company is now roughly 13 years old. It was started at the University of British Columbia, where I was a professor at the time. And from the early days, or in the first, let’s say, decade of the company, we were really focused on a technology-forward strategy.
We were building and integrating proprietary and best-in-class technologies to make a platform for the generation of novel and highly differentiated antibody therapeutics. And the business model behind that, that drove that was a partnership business model.
So we were essentially hired guns for the industry, and we’re the partner of choice when large pharma, highly enabled partners ran into antibody discovery problems where their internal technologies were not up to the task.
And so that business really drove the company for the first 10 years. And the model included early research fees as well as downstream stakes and programs, and we were running this hired gun technology access for a stake in molecules that are moving forward, sort of
